This is the new MLex platform. Existing customers should continue to use the existing MLex platform until migrated.
For any queries, please contact Customer Services or your Account Manager. Dismiss

Tevra opposes Elanco move to dismiss US antitrust claims over flea, tick treatments

( December 16, 2024, 17:10 GMT | Official Statement) -- MLex Summary: Tevra Brands filed an opposition to dismissal of its US antitrust claims against Elanco Health, stating that its action is "distinct and different" from its previous claims against Bayer HealthCare. Elanco's claims that Tevra is barred by res judicata and collateral estoppel would hold Tevra to a heightened pleading standard, and ignores allegations that Elanco has "done more than merely honor the preexisting agreements" with Bayer after acquiring its animal health business operation, Tevra said. Tevra sued Bayer previously, but the jury in that case was never presented with evidence of Elanco's conduct after its August 2020 acquisition of Bayer, the filing to the Northern District of California said.See attached document:...

Prepare for tomorrow’s regulatory change, today

MLex identifies risk to business wherever it emerges, with specialist reporters across the globe providing exclusive news and deep-dive analysis on the proposals, probes, enforcement actions and rulings that matter to your organization and clients, now and in the longer term.


Know what others in the room don’t, with features including:

  • Daily newsletters for Antitrust, M&A, Trade, Data Privacy & Security, Technology, AI and more
  • Custom alerts on specific filters including geographies, industries, topics and companies to suit your practice needs
  • Predictive analysis from expert journalists across North America, the UK and Europe, Latin America and Asia-Pacific
  • Curated case files bringing together news, analysis and source documents in a single timeline

Experience MLex today with a 14-day free trial.

Start Free Trial

Already a subscriber? Click here to login

Documents

Related Sections